Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Search Results to Kenneth Gordon

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Gordon, Kenneth

Item TypeName
Concept Treatment Outcome
Concept Withholding Treatment
Academic Article Treatment of multiple lesions of Bowen disease with isotretinoin and interferon alfa. Efficacy of combination chemotherapy.
Academic Article Comparative tolerability of systemic treatments for plaque-type psoriasis.
Academic Article Evaluation of tissue-engineered skin (human skin substitute) and secondary intention healing in the treatment of full thickness wounds after Mohs micrographic or excisional surgery.
Academic Article Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
Academic Article Severe hidradenitis suppurativa treated with infliximab infusion.
Academic Article Biologic therapy for psoriasis: the new therapeutic frontier.
Academic Article Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
Academic Article Patient education and advocacy groups: a means to better outcomes?
Academic Article Definitions of measures of effect duration for psoriasis treatments.
Academic Article Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
Academic Article A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
Academic Article Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.
Academic Article Duration of remission of biologic agents for chronic plaque psoriasis.
Academic Article Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.
Academic Article Therapeutics and immune-mediated skin disease.
Academic Article Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.
Academic Article Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
Academic Article From laboratory to clinic: rationale for biologic therapy.
Academic Article Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
Academic Article Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.
Academic Article Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
Academic Article Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.
Academic Article Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
Academic Article The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach.
Academic Article Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Academic Article Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Academic Article Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
Academic Article Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
Academic Article Strategies for treatment with anti-tumor necrosis factor agents in psoriasis: maintaining efficacy and safety for the long haul.
Academic Article Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.
Academic Article Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
Academic Article Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis.
Academic Article Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial.
Academic Article Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
Academic Article Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Academic Article Evolution of biologic therapies for the treatment of psoriasis.
Academic Article Remittive effects of intramuscular alefacept in psoriasis.
Academic Article The efficacy of alefacept in the treatment of chronic plaque psoriasis.
Academic Article Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
Academic Article Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity.
Academic Article Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Academic Article Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
Academic Article Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.
Academic Article Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
Academic Article Unmet needs in the treatment of psoriasis.
Academic Article A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Academic Article Understanding therapeutic pathways and comorbidities in psoriasis.
Academic Article A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Academic Article Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
Academic Article Clinical meaningfulness of complete skin clearance in psoriasis.
Academic Article Translating the Science of Psoriasis.
Academic Article A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab.
Academic Article Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Academic Article Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
Academic Article Bowen's disease of the distal digit. Outcome of treatment with carbon dioxide laser vaporization.
Academic Article Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.
Academic Article Botulinum toxin type A for the treatment of axillary Hailey-Hailey disease.
Academic Article Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Academic Article Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Academic Article Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy.
Academic Article Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis.
Academic Article Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications.
Academic Article Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.
Academic Article Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
Academic Article Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory.
Academic Article Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
Academic Article Safety of the new macrolide immunomodulators.
Academic Article Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Academic Article Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Academic Article Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis.
Academic Article Treating to Target-A Realistic Goal in Psoriasis?
Academic Article The Evolving Landscape of Psoriasis Treatment.
Academic Article Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Academic Article Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis.
Academic Article Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials.
Academic Article Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.
Academic Article Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Academic Article Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
Academic Article Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Academic Article Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
Academic Article Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.
Academic Article Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
Academic Article Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study.
Academic Article Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
Academic Article Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.
Academic Article Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.
Academic Article Risankizumab in moderate-to-severe plaque psoriasis.
Academic Article Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2.
Academic Article Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
Academic Article Defining drug-free remission of skin disease in patients with plaque psoriasis.
Academic Article Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
Academic Article Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
Academic Article A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Academic Article Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies.
Academic Article Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.
Academic Article Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).
Academic Article Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.
Academic Article Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
Academic Article Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
Academic Article Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Academic Article Efficacy, safety, usability, and acceptability of risankizumab 150?mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.
Academic Article Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
Academic Article Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.
Academic Article Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.

Search Criteria
  • Therapeutics